Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06270082 · ClinicalTrials.gov registry record · Phase 1
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
A Phase 1 study, sponsored by Ikena Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT06270082: Clinical Trial Phase 1 study, sponsored by Ikena Oncology.
NCT06270082 is a Phase 1 study that was terminated before completion, run by Ikena Oncology. The registered enrollment target is 75 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06270082, a Phase 1 study, was terminated before completion, sponsored by Ikena Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Primary Outcome
• Frequency and severity of treatment-emergent adverse events, including treatment-related adverse events, and serious adverse events
Interventions
- DRUG IK-595
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2025-09-08 |
| Phase | Phase 1 |
Why NCT06270082 stopped before completion
NCT06270082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 1 intervention - of which IK-595 is the first listed.
NCT06270082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06270082 about?
NCT06270082 is a clinical study titled "Study of IK-595 in RAS- or RAF-altered Advanced Tumors". This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumo...
What is the current status of trial NCT06270082?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2023-12-18. Estimated completion is 2025-09-08.
What interventions are being tested in trial NCT06270082?
The interventions under investigation include: IK-595 (DRUG).
Who is sponsoring clinical trial NCT06270082?
This trial is sponsored by Ikena Oncology, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06270082's enrollment target sits among peer trials
75 711th of 2000 higher than 1,276 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI